Compare Nerdwallet Inc (NRDS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs Recursion Pharmaceuticals Inc — how do they compare? Nerdwallet Inc trades at $9.41 (market cap $610.79M), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3× Nerdwallet Inc's market cap, and Nerdwallet Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| NRDS | RXRX | |
|---|---|---|
Market Cap | $610.79M | $1.86B |
Sector | Financials | Health |
52-Week High | $15.93 | $6.79 |
52-Week Low | $7.58 | $2.84 |
Enterprise Value | $525.09M | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRDS trades at $9.56, down 3.24% amid bearish technical signals, though fundamentals show strong improvement with revenue growing from $539M in 2022 to $837M in 2025 and net income turning positive. The stock appears undervalued with a P/E of 10.62 and P/S of 0.79, while analyst sentiment remains positive with 4 out of 6 ratings being Buy. Recent Q2 2026 earnings missed expectations but management highlights an inflection point in business operations.
The outlook is mixed: strong profitability metrics (93.5% gross margin, 18.16% ROE) and analyst price targets suggesting 27.9% upside support bullish case, but technical weakness and competitive pressures in credit card/search segments pose near-term risks. Execution on Q3 guidance and sustained cash flow generation will be critical for stock performance.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
